multiple dose studies [Design Issues]

posted by Loky do – Egypt, 2024-03-11 12:20 (431 d 15:12 ago) – Posting: # 23900
Views: 2,868

❝ As this is FDC- both the drug needs to be analyzed and thus also consider Solifenacin for washout consideration.

I'm a little confused :confused: why to analyze solifenacin as it is immediate release and the concern towards tamsulosin as it is the delayed release one, even if I took into consideration the washout of both, are the results of solifenacin, in this case, affect those of tamsulosin?

Regards,
Loky

Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5! [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,670 registered users;
47 visitors (0 registered, 47 guests [including 12 identified bots]).
Forum time: 04:32 CEST (Europe/Vienna)

By all means let’s be open-minded, but not so open-minded
that our brains drop out.    Richard Dawkins

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5